SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 49.24 |
| Enterprise Value ($M) | 29.55 |
| Book Value ($M) | 17.55 |
| Book Value / Share | 0.64 |
| Price / Book | 2.81 |
| NCAV ($M) | 15.16 |
| NCAV / Share | 0.55 |
| Price / NCAV | 3.25 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.17 |
| Return on Assets (ROA) | -0.97 |
| Return on Equity (ROE) | -1.11 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.47 |
| Current Ratio | 3.47 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 22.76 |
| Assets | 25.14 |
| Liabilities | 7.59 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Hirschman Orin | 5.80 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 55,569 | 267,228 | 20.79 | |
| 79,929 | 247,467 | 32.30 | |
| 91,653 | 367,178 | 24.96 | |
| 110,237 | 438,123 | 25.16 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ICCC – ImmuCell Corporation | IKT – Inhibikase Therapeutics, Inc. |
| IMCC – IM Cannabis Corp. | IMNM – Immunome, Inc. |
| IMNN – Imunon, Inc. |
Financial data and stock pages provided by
Fintel.io